NCT05875168 2026-04-20
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo
Phase 1/2 Recruiting
Clinical Trials
66 trialsNCT07193511 2026-04-16
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT04317105 2026-04-13
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04799054 2026-04-13
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Ascendis Pharma A/S
Phase 1/2 Terminated
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07335497 2026-04-13
ASCEND
Crescent Biopharma, Inc.
Phase 1/2 Recruiting
NCT04713046 2026-04-02
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT07213817 2026-04-01
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
Phase 1/2 Recruiting
NCT07213830 2026-03-31
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
Phase 1/2 Recruiting
NCT04333706 2026-03-10
EMPOWER
University of Southern California
Phase 1/2 Recruiting
NCT05004116 2026-03-04
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT05039632 2026-02-06
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05276284 2026-01-14
TEMPLE
Rigshospitalet, Denmark
Phase 1/2 Completed
NCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT05566574 2025-12-17
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT05731271 2025-12-17
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04266912 2025-11-25
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06311851 2025-11-25
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Pardis Noor Medical Imaging and Cancer Center
Phase 1/2 Recruiting
NCT06184035 2025-11-20
Tumorad
Spago Nanomedical AB
Phase 1/2 Recruiting
NCT05847686 2025-11-05
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
University of Washington
Phase 1/2 Completed
NCT05384626 2025-10-30
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT05118789 2025-10-24
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Nuvalent Inc.
Phase 1/2 Recruiting
NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
NCT05898399 2025-10-15
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma Ltd
Phase 1/2 Active not recruiting
NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04701281 2025-09-18
SYS-CAPLIOX
AllVascular
Phase 1/2 Terminated
NCT05220098 2025-08-29
First-in-Human Study of TAK-280 in Participants With Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05394103 2025-08-17
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Qurient Co., Ltd.
Phase 1/2 Recruiting
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT05159388 2025-07-08
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
Servier
Phase 1/2 Completed
NCT06154291 2025-06-22
FIPO23
Xenothera SAS
Phase 1/2 Recruiting
NCT04706715 2025-05-31
LAG3 PET Imaging in Advanced Solid Tumors
University Medical Center Groningen
Phase 1/2 Active not recruiting
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT05674825 2025-05-15
MCW I-PREDICT
Medical College of Wisconsin
Phase 1/2 Recruiting
NCT06395090 2025-04-08
MK-9999-01B
Merck Sharp & Dohme LLC
Phase 1/2 Withdrawn
NCT04761198 2025-03-17
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
Mereo BioPharma
Phase 1/2 Completed
NCT05862324 2025-02-14
TACTIC-3
Triumvira Immunologics, Inc.
Phase 1/2 Active not recruiting
NCT04574583 2025-02-03
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04866134 2024-08-27
HERKULES-1
Erasca, Inc.
Phase 1/2 Active not recruiting
NCT05176665 2024-08-26
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT04618393 2024-05-21
A Study of EMB-02 in Participants With Advanced Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 1/2 Terminated
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting
NCT04029181 2024-05-03
ImmunoPET With an Anti-CD8 Imaging Agent
University Medical Center Groningen
Phase 1/2 Unknown
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
NCT05289076 2023-12-01
CRLM-Z
University Hospital, Linkoeping
Phase 1/2 Unknown
NCT05947487 2023-07-17
CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05268666 2023-06-15
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Jubilant Therapeutics Inc.
Phase 1/2 Unknown
NCT00886782 2023-04-28
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Terminated